[High-dosage gestagen long-term therapy in corpus carcinoma; influence on survival time (author's transl)].
D000368:Aged; D005260:Female; D006801:Humans; D008017:Life Expectancy; D008524:Medrogestone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D011245:Pregnadienes / Q000008:administration & dosage*; D011379:Prognosis; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality
D011245:Pregnadienes; D008524:Medrogestone; D008525:Medroxyprogesterone
Hochdosierte Gestagen-Langzeittherapie beim Korpuskarzinom, Einfluss auf Uberlebenszeit.